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Myocardial infarction is a common clinical presentation of ischemic heart disease, a leading cause of death worldwide 1 . Excessive neurohumoral activity, including sympathetic stimulation and reninangiotensin-aldosterone activation, promotes heart failure and sudden death in individuals with myocardial infarction. Myocardial CaMKII is now recognized as a downstream signal that is necessary for the pathological responses to β-adrenergic-receptor agonist 2 and Ang II (ref.
3) stimulation, but the potential intersection between CaMKII and cardiac aldosterone signaling is unexplored. Circulating aldosterone concentrations increase in individuals after myocardial infarction 4 , and augmented plasma aldosterone concentrations increase the risk of early mortality after myocardial infarction 5 . Aldosterone activates the mineralocorticoid receptor, and although antagonists of this receptor substantially reduce mortality after myocardial infarction 6, 7 , the cellular pathways activated by aldosterone that contribute to increased mortality after myocardial infarction are largely unknown. Aldosterone favors renal sodium reabsorption in the distal convoluted tubule 8 , but recent evidence suggests that aldosterone has direct effects on the myocardium to increase the amount of reactive oxygen species (ROS) 9, 10 . We recently identified a molecular mechanism in which CaMKII is activated during myocardial infarction or by infusion of Ang II by oxidation of paired methionines (Met281 and Met282) in the CaMKII regulatory domain 3 . The apparent association of aldosterone with an increased amount of myocardial ROS and premature death suggests that oxidized CaMKII (ox-CaMKII) could have a key role in the pathological responses to aldosterone signaling in the heart. Using a mouse myocardial infarction model, we infused aldosterone to approximate the plasma aldosterone concentrations measured in patients with myocardial infarction 11, 12 . We found enhanced cardiac rupture in these mice compared to mice with myocardial infarction infused with vehicle, with a corresponding increase in CaMKII activity and upregulation of matrix metalloproteinase 9 (encoded by Mmp9). Our findings reveal a previously unidentified role for CaMKII in the aldosterone pathway and highlight a previously unknown ability of myocytes to adversely affect the cardiac matrix after myocardial infarction.
RESULTS

Aldosterone stimulates CaMKII oxidation and activation
Within 15 min after administration, aldosterone stimulated cardiac ROS, as detected by the ROS fluorescent indicator dihydroethidium (DHE), in wild-type (WT) mice and, to a significantly lesser degree, in Ncf1 −/− (p47 phox−/− ) mice, which lack functional NADPH oxidase 13 (P = 0.003 by analysis of variance (ANOVA); P < 0.05 for Ncf1 −/− given aldosterone versus WT given aldosterone; P < 0.01 for WT given aldosterone versus WT given vehicle by Bonferroni's multiple comparison test; Fig. 1a ). To determine whether aldosterone can stimulate CaMKII oxidation, we measured ox-CaMKII levels in hearts from aldosterone-and vehicle-infused mice using an antiserum against oxidized Met281-Met282 in the CaMKII autoregulatory domain 3 . We detected increased ox-CaMKII levels by immunofluorescence (Fig. 1b) and by immunoblotting of heart lysates from aldosteroneinfused mice compared to vehicle-infused mice (P = 0.021; Supplementary Fig. 1a) , and we confirmed that increased ox-CaMKII levels led to an increase in Ca 2+ /calmodulin-autonomous CaMKII activity without a change in total CaMKII activity (P = 0.019; Fig. 1c ) in the myocardia of aldosterone-infused mice compared to vehicle-infused mice. We previously showed that Ang II infusion can increase CaMKII oxidation 3, 14 . To determine whether aldosterone contributes to the increase in myocardial ox-CaMKII after treatment with Ang II, we infused mice for 6 d with Ang II in the presence or absence of the mineralocorticoid receptor antagonist spironolactone. We found that hearts from mice infused with Ang II and spironolactone had a similar degree of CaMKII oxidation compared to mice that received Ang II and vehicle ( Supplementary Fig. 1b) , suggesting that Ang II can increase ox-CaMKII independently of aldosterone. Alternatively, an increase in Ca 2+ /calmodulin-autonomous CaMKII activity can result from Thr287 autophosphorylation. We found that the level of cardiac CaMKII Thr287 phosphorylation was similar in vehicle-and aldosterone-infused mice (Supplementary Fig. 1c ), consistent with a view that aldosterone increases CaMKII activity preferentially by Met281-Met282 oxidation.
We next used cultured neonatal myocytes to further characterize the mechanism underlying aldosterone-induced ROS and CaMKII oxidation. Neonatal myocytes responded to a low concentration of aldosterone (10 −9 mol l −1 ) with increased ROS, as detected by DHE (Supplementary Fig. 2a,b) , in agreement with the published K d value of mineralocorticoid receptor for aldosterone 15 , suggesting that aldosterone acts through the mineralocorticoid receptor to induce ROS. Furthermore, both ROS and ox-CaMKII levels were reduced by the mineralocorticoid receptor antagonist spironolactone (Fig. 1d) . These findings support the hypothesis that aldosterone-stimulated ROS production and CaMKII oxidation require the mineralocorticoid receptor and suggest the possibility that some of the clinical benefit to patients with myocardial infarction treated with spironolactone is derived from myocardial CaMKII inhibition.
NADPH oxidase is activated by aldosterone in endothelial cells 16 , and NADPH oxidase is an effective source of ROS for oxidizing CaMKII in the myocardium 3 . Because Ncf1 −/− mice showed partial protection from aldosterone-stimulated cardiac ROS (Fig. 1a) , we investigated the potential role of NADPH oxidase in aldosteroneinduced CaMKII oxidation. Pretreatment with the NADPH oxidase inhibitor apocynin prevented aldosterone-stimulated ROS and CaMKII oxidation in neonatal myocytes (Fig. 1d) . Because Rac1 is essential for NADPH oxidase activation by mineralocorticoid receptor in endothelial cells 16 , we next examined the potential requirement for Rac1 by infecting neonatal myocytes with an adenovirus expressing a dominant-negative form of the small GTPase Rac1 (N17rac1) 17 . N17rac1 prevented aldosterone-induced ROS generation (Fig. 1e) , For the summary data, overall P = 0.003 by one-way ANOVA. *P < 0.05, **P < 0. consistent with the hypothesis that mineralocorticoid receptor couples to the NADPH oxidase complex by a Rac1-dependent process in the myocardium. Taken together, these findings suggest that aldosterone increases myocardial ROS levels by mineralocorticoid receptor and Rac1-dependent activation of NADPH oxidase, leading to increased ox-CaMKII levels.
Myocardial MsrA overexpression lowers ox-CaMKII levels As methionine oxidation is a recently discovered mechanism for CaMKII activation, we sought to better understand the regulation of this dynamic process. Hearts from mice lacking methionine sulfoxide reductase A (MsrA) in all tissues show increased susceptibility to CaMKII oxidation by Ang II and increased mortality after myocardial infarction 3 . To test if myocardial MsrA supplementation could reduce the amount of ox-CaMKII after aldosterone administration, we infected neonatal myocytes with an adenovirus expressing human MsrA. MsrA overexpression reversed aldosterone-stimulated CaMKII oxidation (Fig. 2a) , suggesting that endogenous concentrations of MsrA in WT myocytes are insufficient for maximal methionine reductase activity against oxidized CaMKII. We next developed a mouse model of myocardial-restricted MsrA overexpression to determine if CaMKII oxidation is essential to aldosterone-induced pathology in vivo. MsrA transgenic mice had increased MsrA protein expression (Fig. 2b) and reductase activity (Fig. 2c) compared to WT littermates. MsrA transgenic mice had similar baseline left ventricular ejection fractions compared to WT littermates (Supplementary Fig. 3) . However, the amount of oxCaMKII was considerably diminished in hearts from MsrA transgenic mice compared to WT littermates in response to aldosterone infusion (Fig. 2d) . In contrast, and unlike NADPH oxidase deficiency, MsrA overexpression had no effect on aldosterone-induced total ROS production (Fig. 2e) , as detected by DHE fluorescence, suggesting that MsrA overexpression results in a highly targeted antioxidant effect.
Myocardial infarction and aldosterone promote cardiac rupture
Our data indicate that aldosterone increases the amount of oxidized and activated CaMKII in myocytes in vivo and in vitro. We next investigated how CaMKII activation could contribute to the cardiotoxic effects of aldosterone after myocardial infarction. After myocardial infarction in humans, plasma aldosterone concentrations may elevate to 20-fold excess over baseline 18 and to as high as 1 × 10 −7 mol l −1 (ref. 12). We measured plasma aldosterone concentrations in mice after myocardial infarction but found only a modest (approximately twofold) increase, suggesting that robust elevation in circulating aldosterone concentrations after myocardial infarction is not characteristic of mice. To 'humanize' our mouse model, we infused mice with aldosterone to reach a concentration sevenfold over baseline (low dose), similar to that commonly observed in humans with heart failure 19 . In addition, to mimic what is seen in very high risk individuals with severely elevated Aldo after myocardial infarction 11, 12 , we infused mice with aldosterone to approximate a 20-fold increase in circulating aldosterone concentration over baseline (high dose) ( Supplementary Fig. 4 ). WT mice infused with aldosterone and subjected to myocardial infarction (MI+Aldo mice) had significantly reduced survival at the high dose and showed a trend toward reduced survival at the low dose within the first 5 d after surgery, as compared to WT mice infused with vehicle and subjected to myocardial infarction (MI+Veh mice; 34.5% survival with high-dose aldosterone compared to 69.0% survival with vehicle (P = 0.007) and 42.9% survival with lowdose aldosterone compared to 69.0% survival with vehicle (P = 0.083); Fig. 3a) . Notably, excess mortality in the MI+Aldo group was a result of cardiac rupture (Fig. 3b,c) . Because MI+Aldo mice given the high dose of aldosterone had the most prominent rupture and mortality phenotype, we used the high dose in all subsequent studies.
Two weeks after myocardial infarction, we found significantly increased ox-CaMKII levels in cardiac lysates from MI+Aldo mice as compared to mice with sham surgery (P = 0.039; Fig. 3d ). Moreover, Ca 2+ /calmodulin-autonomous CaMKII activity was elevated in cardiac lysates at 1 week after myocardial infarction in MI+Aldo compared to MI+Veh mice (P < 0.001; Fig. 3e ). As aldosterone can increase blood pressure and contribute to heart failure after myocardial infarction by increasing renal sodium reabsorption and intravascular volume 18 , we next tested whether an increase in blood pressure could contribute to cardiac rupture in MI+Aldo mice. The blood pressure in WT mice infused with aldosterone for 2 weeks was, however, not significantly different compared to vehicle-infused mice ( Supplementary  Fig. 5a-c) , probably because our model did not include increased dietary sodium. To test this hypothesis, we repeated the aldosterone infusion in mice whose drinking water was supplemented with 1% NaCl and 0.75% KCl and found a significant increase in systolic blood pressure (P = 0.020; Supplementary Fig. 5d-f) . Likewise, myocardial infarction itself did not significantly increase blood pressure ( Supplementary Fig. 5g-i) . Echocardiographic measurements, performed at 3-6 d after surgery (the time period during which rupture predominantly occurred) indicated equivalent myocardial function in MI+Aldo and MI+Veh mice, and these measurements were similar between MI+Aldo mice succumbing to cardiac rupture and MI+Aldo mice resisting rupture (Supplementary Fig. 6 ). However, there was a trend toward a decreased ejection fraction in MI+Aldo mice with rupture compared to MI+Aldo mice with no rupture (P = 0.189; Supplementary Fig. 6r ), suggesting that increased contractile force is unlikely to underlie the increased propensity toward cardiac rupture in this model. Thus, excessive death caused by cardiac rupture in MI+Aldo mice was associated with increased levels of ox-CaMKII and autonomous CaMKII activity but was independent of effects on blood pressure and myocardial contraction.
CaMKII inhibition protects against cardiac rupture Myocardial CaMKII inhibition is known to reduce adverse left ventricular remodeling 3 weeks after myocardial infarction 2,3 . However, to our knowledge, the potential of myocardial CaMKII to affect mortality after myocardial infarction is untested. Given the elevated CaMKII activity present in MI+Aldo mice, we hypothesized that CaMKII inhibition might improve survival. Accordingly, we observed a significant survival advantage in mice with genetic, myocardialspecific CaMKII inhibition (AC3-I mice) compared to WT mice in the first week after myocardial infarction (P = 0.007; Fig. 3f ). In AC3-I mice subjected to the MI+Aldo protocol, we found a trend toward protection from mortality (73.7% survival for MI+Aldo AC3-I mice compared to 33.3% survival for MI+Aldo WT littermates (P = 0.075; Fig. 3g) ). MI+Aldo AC3-I mice had a low incidence of cardiac rupture, similar to that of MI+Veh AC3-I mice (Fig. 3h) , suggesting that the acute effects of aldosterone in promoting cardiac rupture after myocardial infarction require myocardial CaMKII activity.
To determine the role of ox-CaMKII in survival following MI+Aldo, we repeated the myocardial infarction studies in Ncf1 −/− and MsrA −/− mice, as well as in MsrA transgenic mice, which we generated for this study. Ncf1 −/− mice were protected from MI+Aldo-induced cardiac rupture (with 0/11 mice in this group having cardiac rupture), supporting the importance of ROS in cardiac rupture after myocardial infarction. MsrA −/− mice showed enhanced myocardial apoptosis, maladaptive left ventricular remodeling and increased mortality after myocardial infarction 3 . We found a pronounced susceptibility to rupture in MsrA −/− MI+Aldo mice (7/10 mice in this group had cardiac rupture), whereas MsrA transgenic MI+Aldo mice had a survival advantage (P = 0.048; Fig. 3i ) and were protected from cardiac rupture compared to MI+Aldo WT littermates (P = 0.047; Fig. 3j ). These studies showed that conditions favoring suppression of myocardial ox-CaMKII dramatically improve survival by reducing cardiac rupture in the first week after myocardial infarction. 
CaMKII increases MMP9 expression
We next focused on the gelatinases MMP2 and MMP9, which are known mediators of the cardiac rupture phenotype in mice 20, 21 . We used a gene array comparing mRNA isolated from AC3-I and control hearts after myocardial infarction 22 to identify candidate CaMKIIregulated genes that could contribute to ventricular rupture. These gene array data pointed to a difference in Mmp9 expression, which we confirmed using quantitative RT-PCR (qRT-PCR): after myocardial infarction, Mmp9 expression was increased to a significantly lesser degree in AC3-I compared to WT mice (Fig. 4a) . Neutrophils and macrophages are the predominant sources of MMP9 release after myocardial infarction 21, 23 . However, because CaMKII activity is inhibited specifically in cardiomyocytes in AC3-I mice 2 , we felt it more likely that the decrease in MMP9 expression occurred in cardiomyocytes. As assessed by immunofluorescence using z-stack analysis of images acquired by confocal microscopy, MI+Aldo treatment significantly increased the amount of MMP9 in ventricular cardiomyocytes isolated from the infarcted region in WT but not AC3-I adult mice as compared to cardiomyocytes isolated from adult sham-operated control mice (Fig. 4b) . z-stack analysis further showed that MMP9 expression was cytoplasmic and that MMP9 staining was oriented perpendicularly to that of α-actinin (Fig. 4b) . These findings suggest that myocardial infarction-provoked cardiac rupture requires a CaMKII-dependent increase in myocardial MMP9 expression. We repeated the immunofluorescence and z-stack analyses on human heart samples obtained from individuals who had died of myocardial infarction with or without rupture. In samples from individuals with rupture, but not in those from individuals without rupture, we found an increase in punctate intracellular staining of MMP9 in cardiomyocytes located in the infarcted region compared to those located in the remote region (Fig. 4c) . Thus, our findings reveal a parallel increase in cardiomyocyte-derived MMP9 in mice and humans that correlates with cardiac rupture.
Given the contribution of infiltrating immune cells to MMP9 release 21, 23 , we next assessed whether myocardial CaMKII inhibition might have effects on the cellular response to myocardial infarction. We analyzed myeloperoxidase (MPO), a marker of neutrophil content 24 , and found that both MPO immunohistochemical staining (Fig. 5a ) and MPO activity (Fig. 5b) increased after myocardial infarction but were similar in WT and AC3-I mice 24 h after MI+Aldo treatment. The number of MPO-positive cells was also similar in samples from WT MI+Aldo mice with and without cardiac rupture (Fig. 5a) . We also stained for Mac-3, a macrophage marker, as macrophages are the predominant cell type in the delayed inflammatory influx that follows neutrophil accumulation 21 . In samples 3 d after MI+Aldo treatment, we found no difference in the level of Mac-3 staining between WT and AC3-I mice (Fig. 5c) . We next asked if the protection from cardiac rupture in AC3-I compared to WT mice after MI+Aldo treatment was due to reduced MMP9 expression in infiltrating inflammatory cells. We performed double immunostaining for the neutrophil membrane marker NIMP-R14 (ref. 25 ) and MMP9 and for Mac-3 and MMP9 in hearts from WT MI+Aldo and AC3-I MI+Aldo mice. We found no significant differences in MMP9 expression in NIMP-R14 or Mac-3-positive cells between WT and AC3-I mice (P = 0.787 and P = 0.329, respectively; Supplementary Fig. 7) , suggesting that inflammatory cells in WT and AC3-I mice produce similar amounts of MMP9. We next assessed cardiac fibrosis after myocardial infarction by examining profibrotic genes known to be activated in cardiomyocytes by a myocyte enhancer factor transcriptional pathway 26 . We found that the levels of Col1a2 and Col3a1 mRNA were increased after MI+Aldo treatment of WT mice but were reduced after MI+Aldo treatment of AC3-I mice (Fig. 5d) . In contrast, Ctgf mRNA expression increased equally in WT and AC3-I mice after MI+Aldo treatment. Total collagen deposition, as assessed by Masson's trichrome staining, revealed similar increases in the amount of collagen after MI+Aldo treatment of WT and AC3-I mice (Fig. 5e) . We interpret these data as indicating that in the setting of myocardial infarction and aldosterone infusion, myocardial CaMKII inhibition suppresses myocardial MMP9 expression without affecting the fibrotic response.
Aldosterone regulates Mmp9 promoter activity
We next challenged neonatal myocytes with aldosterone and found a significant increase in MMP9 activity by gelatin zymography, whereas MMP2 activity, which is also detectable by this method, was not significantly changed (Fig. 6a) . We validated Mmp9 as a transcriptionally regulated target in neonatal myocytes (Fig. 6b) , an effect that was attenuated in the presence of the mineralocorticoid receptor antagonist spironolactone (Supplementary Fig. 2c ). CaMKII activity was crucial for aldosterone-stimulated Mmp9 expression, as this response was blocked in myocytes which had received pretreatment with an shRNA targeting the major myocardial CaMKII isoform (CaMKIIδ) (Fig. 6b) . Adenoviral overexpression of CaMKII in neonatal myocytes was sufficient to drive an increase in Mmp9 expression (Fig. 6c) . Because Mmp9 −/− mice are known to resist myocardial infarctioninduced cardiac rupture 21 , we subjected Mmp9 −/− mice to MI+Aldo treatment and observed a trend toward protection from rupture (1/8 Mmp9 −/− mice had rupture compared to 8/13 control C57BL/6 mice (P = 0.067)), supporting the concept that MMP9 is needed for increased cardiac rupture in MI+Aldo treated mice.
In astrocytes, CaMKII acts via JNK and c-Jun activation and the subsequent recruitment of the transcription factor AP-1 to the Mmp9 promoter to induce MMP9 (ref. 27 ). However, we found no statistical differences between the levels of JNK and c-Jun phosphorylation in cardiac lysates of mice infused with Aldo or vehicle ( Supplementary  Fig. 8) , suggesting that AP-1 recruitment is not a major component of aldosterone-induced cardiac signaling activated in these mice. We next analyzed the mouse Mmp9 gene promoter for potential CaMKII-respon- Ctgf, the gene encoding connective tissue growth factor; Col1a2, the gene encoding collagen type I alpha 2; Col3a1, the gene encoding collagen type III alpha 1. n ≥ 4 mice per group; the indicated overall P values were determined by one-way ANOVA for each bracketed group. ***P < 0.001 by Bonferroni's multiple comparison test. (e) Masson's trichrome staining showed a similar increase in fibrosis after MI+Aldo treatment in WT and AC3-I mice. P values were determined using a Student's t test; n ≥ 3 mice per group. Black scale bars, 2 mm; white scale bars, 50 µm. AU, arbitrary units. Data are means ± s.e.m.
sive regulatory sequences and identified an A/T-rich element, similar to other validated binding sites for myocyte enhancer factor 2 (MEF2), located approximately 670 bp upstream of the Mmp9 transcription start site 28 (Fig. 6d) . CaMKII is a known upstream activator of MEF2 through phosphorylation-dependent derepression of transcription by type II histone deacytelases 29 . We focused on this candidate MEF2 binding site because aldosterone infusion significantly increased MEF2-driven β-galactosidase activity in the hearts of MEF2-lacZ reporter mice 30 compared to vehicle-infused controls (Fig. 6e) . Aldosterone-induced MEF2 activation was eliminated by interbreeding the MEF2-lacZ reporter mice with AC3-I mice (MEF2 × I mice) (Fig. 6e) , indicating that myocardial CaMKII activity was required for this activation. To determine whether the putative MEF2 binding site was functional, we examined the effects of aldosterone on neonatal myocytes containing intact or mutated versions of an Mmp9-promoter-luciferase reporter construct (Fig. 6d) . Aldosterone treatment significantly increased Mmp9-promoter-driven luciferase activity of the intact but not mutated construct (Fig. 6f) , indicating that the identified region is crucial for aldosterone-mediated transcription of Mmp9. Mmp9 is distinct from canonical MEF2 gene targets, which are involved in muscle differentiation, development and hypertrophy 30, 31 . Taken together, our data indicate that cardiomyocyte MMP9 expression is upregulated in the setting of myocardial infarction and aldosterone infusion through a pathway involving CaMKII oxidation and MEF2-dependent transcription (Fig. 6g) .
DISCUSSION
Our study supports a key role for ROS and myocardial CaMKII in cardiac matrix biology and disease. We show that in the setting of myocardial infarction and high aldosterone levels, CaMKII activation causes mortality due to cardiac rupture with concurrent upregulation of MMP9. Although MMP9 is known to increase cardiac rupture after myocardial infarction, it had previously been presumed that the source of MMP9 was exclusively infiltrating immune cells 21 . Although our results do not rule out the contribution of extramyocardial MMP9 or other proteolytic enzymes (which are likely to also be upregulated in this mouse model) to remodeling after myocardial infarction, they provide evidence for the contribution of cardiomyocyte-delimited CaMKII to a critical threshold of MMP9 activity in the heart. Moreover, although we did not find differences between WT and AC3-I mice in the overall numbers of infiltrating neutrophils or macrophages or in the level of MMP9 expression in these cells, our findings do not exclude the possibility that other functional differences in infiltrating inflammatory cells may contribute to the protective effects of myocardial CaMKII inhibition. Evidence for the active participation of the myocardium in proinflammatory signaling was also provided in another recent study, in which myocardial infarction led to CaMKIIdependent activation of NF-κB-mediated transcription 22 . A previous study found that MEF2-induced Mmp10 transcription is detrimental to vasculogenesis 32 , suggesting that our findings may have far-reaching implications for other processes in which elevated ROS and hyperactive matrix remodeling have key roles in disease progression, such as cancer metastasis 33 , atherosclerosis 34 and stroke 35 . Although the role of an ox-CaMKII pathway in the promotion of myocardial MMP9 expression remains unproven in humans, we observed increased myocardial MMP9 levels with rupture after myocardial infarction in mice and humans. Short-term metalloproteinase inhibition was previously shown to protect against cardiac rupture, but long-term metalloproteinase inhibition led to cardiac dysfunction and premature death as a result of defective neovasculogenesis 21 . These results, combined with previous work from our group and others on the cardioprotective benefits of CaMKII inhibition in structural heart disease 2, 14, 36, 37 , suggest that CaMKII inhibition may be a viable alternative to global metalloproteinase inhibition for preventing or reducing the incidence of cardiac rupture and death after myocardial infarction. Excessive oxidation is a fundamental feature of major cardiovascular diseases and is linked to a wide array of processes associated with maladaptive responses to myocardial infarction, including myocardial hypertrophy 38, 39 , apoptosis 3 , interstitial fibrosis 38, 39 , increased matrix metalloproteinase activity 39 , inflammation 22 and dilation of the left ventricular cavity 3,38 . However, broad spectrum antioxidant supplements have not been beneficial in clinical trials [40] [41] [42] , although preliminary studies with antioxidants engineered for local action 43 and molecular specificity 44 seem to show benefit. The failure of broad spectrum antioxidant supplements coupled with the preliminary success of molecularly and subcellularly targeted antioxidants suggest that an improved understanding of ROS-responsive disease pathways will be necessary to identify and develop useful new treatments designed to interrupt pathological oxidation processes locally, in the specific signaling pathways most relevant to the progression of cardiovascular disease 45 .
Human myocardium after myocardial infarction shows elevated NADPH oxidase activity 46 , and hearts from Ncf1 −/− mice lacking functional NADPH oxidase are protected from increases in ROS, adverse left ventricular remodeling and death after myocardial infarction surgery 38 . Our results suggest that ROS acts through CaMKII to promote cardiac rupture, as shown, for example, by the protective effects of transgenic overexpression of MsrA.
Neurohumoral pathways initiated by β-adrenergic receptor agonists 47 , Ang II (ref. 48 ) and aldsoterone 6, 7 are major therapeutically validated targets for reducing mortality and heart failure after myocardial infarction. CaMKII is now recognized to be a downstream signaling protein activated by the β-adrenergic 2 and Ang II (ref.
3) pathways in myocardium, and CaMKII inhibition prevents or attenuates myocardial infarction-induced, isoproterenol-induced and Ang II-induced myocardial hypertrophy, apoptosis and dysfunction 2,3,49 . Here we show that CaMKII is also activated in myocytes by aldosterone through a mineralocorticoid receptor pathway that is not coupled to G-protein receptors, and we also show that CaMKII is required for the early pathological effects of aldosterone after myocardial infarction when both CaMKII activity and ROS levels become elevated. Together with earlier results 2,3 , our new findings identify CaMKII as a 'master' signaling node for the neurohumoral pathways targeted by frontline drugs used to treat patients after myocardial infarction.
Cardiac rupture occurs as an early consequence of myocardial infarction and is a particularly challenging clinical problem because it occurs with minimal warning and progresses rapidly to death in the majority of instances despite surgical intervention 50 . Development of preventative therapy is limited by a lack of a molecular understanding of the underlying signaling pathways. The reported incidence of cardiac rupture among myocardial infarction-associated in-hospital deaths can be as high as 15% (ref. 50) , similar to the incidence we observed in mice subjected to myocardial infarction without aldosterone treatment. Rupture is the second major cause of cardiac sudden death within the first month after myocardial infarction 51 . Current recommendations support initiation of β-adrenergic-receptor and Ang II antagonist drugs immediately after diagnosis of myocardial infarction 52, 53 , and our study provides a new mechanistic rationale for a recently initiated clinical study of rapid initiation of mineralocorticoid receptor antagonist drugs to reduce the incidence of mortality after myocardial infarction 54 , including mortality caused by ventricular rupture.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
